Analysts Set Expectations for PRAX Q3 Earnings

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) – Equities research analysts at Lifesci Capital issued their Q3 2025 earnings estimates for Praxis Precision Medicines in a research report issued on Wednesday, September 3rd. Lifesci Capital analyst F. Brisebois anticipates that the company will post earnings of ($3.57) per share for the quarter. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Praxis Precision Medicines’ current full-year earnings is ($10.22) per share. Lifesci Capital also issued estimates for Praxis Precision Medicines’ Q4 2025 earnings at ($3.26) EPS, FY2025 earnings at ($13.42) EPS, Q1 2026 earnings at ($3.41) EPS, Q2 2026 earnings at ($3.07) EPS, Q3 2026 earnings at ($3.40) EPS, Q4 2026 earnings at ($3.39) EPS and FY2026 earnings at ($13.26) EPS.

A number of other equities research analysts have also issued reports on PRAX. HC Wainwright restated a “buy” rating and set a $115.00 price target (up previously from $105.00) on shares of Praxis Precision Medicines in a report on Tuesday, August 5th. Chardan Capital reaffirmed a “buy” rating and set a $80.00 price objective on shares of Praxis Precision Medicines in a research report on Tuesday, July 29th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Praxis Precision Medicines in a research report on Tuesday. Oppenheimer boosted their price objective on shares of Praxis Precision Medicines from $97.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, July 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $80.00 price objective on shares of Praxis Precision Medicines in a research report on Thursday, June 12th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $85.88.

Praxis Precision Medicines Price Performance

PRAX stock opened at $46.85 on Friday. Praxis Precision Medicines has a 52-week low of $26.70 and a 52-week high of $91.83. The company’s 50 day simple moving average is $49.46 and its 200-day simple moving average is $43.41. The firm has a market capitalization of $986.19 million, a P/E ratio of -3.81 and a beta of 2.61.

Praxis Precision Medicines (NASDAQ:PRAX) last released its quarterly earnings results on Monday, August 4th. The company reported ($3.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.40) by $0.09. Praxis Precision Medicines had a negative net margin of 2,137.48% and a negative return on equity of 60.07%.

Institutional Trading of Praxis Precision Medicines

Several large investors have recently added to or reduced their stakes in PRAX. Adage Capital Partners GP L.L.C. grew its position in Praxis Precision Medicines by 188.1% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,742,758 shares of the company’s stock worth $65,998,000 after acquiring an additional 1,137,748 shares in the last quarter. Janus Henderson Group PLC grew its position in Praxis Precision Medicines by 77.5% in the fourth quarter. Janus Henderson Group PLC now owns 929,523 shares of the company’s stock worth $71,621,000 after acquiring an additional 405,957 shares in the last quarter. Driehaus Capital Management LLC grew its position in Praxis Precision Medicines by 192.0% in the first quarter. Driehaus Capital Management LLC now owns 481,598 shares of the company’s stock worth $18,238,000 after acquiring an additional 316,686 shares in the last quarter. VR Adviser LLC boosted its holdings in shares of Praxis Precision Medicines by 40.2% during the 4th quarter. VR Adviser LLC now owns 989,985 shares of the company’s stock worth $76,189,000 after buying an additional 283,854 shares during the period. Finally, Vivo Capital LLC bought a new stake in shares of Praxis Precision Medicines during the 2nd quarter worth $7,048,000. 67.84% of the stock is owned by institutional investors.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.